Altered metabolism of tacrolimus in hepatic veno-occlusive disease

Takehiko Mori, Takayuki Shimizu, Rie Yamazaki, Tomonori Nakazato, Yasuo Ikeda, Shincihiro Okamoto

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Tacrolimus is widely used for the prophylaxis and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (HSCT) and graft rejection in solid organ transplantation. The metabolism of tacrolimus has been reported to be impaired in association with liver dysfunction, mostly as documented in liver transplant recipients. Hepatic veno-occlusive disease (VOD) is one of the serious complications after allogeneic HSCT. It is characterized by jaundice, fluid retention, and painful hepatomegaly, caused by endothelial cell injury resulting from the toxicity of the conditioning regimen. The impaired metabolism of tacrolimus in hepatic VOD has not previously been reported in the literature. Here, we report the notable alteration in the metabolism of tacrolimus in two patients with hepatic VOD, in whom the half-lives of tacrolimus were markedly prolonged (288 and 146 h).

Original languageEnglish
Pages (from-to)1215-1217
Number of pages3
JournalTransplant International
Issue number10
Publication statusPublished - 2005 Oct


  • Hematopoietic stem cell transplantation
  • Hepatic VOD
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Altered metabolism of tacrolimus in hepatic veno-occlusive disease'. Together they form a unique fingerprint.

Cite this